Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Which Exhibition hall Do You Suggest? Vote - 2Some are walking out. Some are shouting. Some are oblivious. How kids are reacting to THAT 'Wicked: For Good' scene
- 35 Eating routine Well disposed Snacks to Keep You Fulfilled
- 4Supercharge Your Remote Work Arrangement with These Game-Changing Instruments
- 5Artemis II crew take new photo of far side of the moon
- Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- How Skoda Lost Its Biggest Market In Just Seven Years
- Iran War Derails The Automotive Industry
- CMA Awards 2025: Full list of nominations, from Entertainer of the Year to Album of the Year
- Iran warns its ready to open new front in Yemen, close Bab al-Mandab Strait with Houthis
- What you need to know about desalination, a growing source of drinking water
- Sustaining Public activity and Connections: Key Methodologies
- Banks for High Fixed Store Rates: Amplify Your Reserve funds
- More than 800 flights canceled as FAA cuts traffic at 40 major airports. Here's what to know.
